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Precise: We highlight the serious adverse effects of fixed high-dose denosumab in 
adolescents including osteonecrosis of the jaw on treatment and rebound hypercalcaemia 
following treatment cessation. 
Key Words: Antiresorptive therapy, bisphosphonates, bone remodelling, rebound 





Context: Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, is 2 
an approved treatment for giant cell tumour of bone (GCTB) in adults and ‘skeletally mature’ 3 
adolescents. Safety concerns include oversuppression of bone remodelling, with risk of 4 
osteonecrosis of the jaw [ONJ] and atypical femur fractures during treatment in adults, and 5 
rebound hypercalcaemia after treatment cessation in children. To date, ONJ has never been 6 
reported in children or adolescents. 7 
Objectives: To describe serious adverse effects during and following high-dose denosumab 8 
therapy in GCTB patients.  9 
Patients: Two adolescents (14 and 15 years) and a young adult (40 years) received fixed 10 
denosumab for GCTB for 1.3 - 4years (cumulative dose 47-98 mg/kg), which was stopped 11 
due to development of ONJ in one adolescent and bilateral femoral cortical stress reactions in 12 
the young adult. All three patients developed rebound hypercalcaemia with acute kidney 13 
injury 5.5 - 7 months after denosumab cessation.  14 
Results: The ONJ necessitated surgical debridement. Rebound hypercalcaemia (serum 15 
calcium 3.1-4.3mmol/L) was unresponsive to hyperhydration alone, requiring repeated doses 16 
of calcitonin or intravenous bisphosphonate treatment. Hypercalcaemia recurred in 2 patients 17 
within 4 weeks, with normal serum calcium profiles thereafter. All patients were naïve to 18 
chemotherapy, radiotherapy, bisphosphonates, corticosteroids and metastases free, 19 
confirming the causative role of denosumab in these complications. 20 
Conclusion: These suppression-release effects of high-dose denosumab on bone remodelling 21 
raise questions about safety of fixed dosing and treatment duration. In young people weight-22 
adjusted dosing and safety monitoring during and after antiresorptive therapy is required. 23 




Giant cell tumour of bone (GCTB) is a benign, locally aggressive tumour with malignant 26 




 decade of life. The majority of 27 
patients are effectively treated with intralesional curettage whilst some patients with 28 
extensive, aggressive, and/or incompletely resectable tumours require excision and 29 
reconstruction or even joint sacrificing surgery given the predilection of the tumour for 30 
apophyseal locations (1). 31 
GCTB is characterised by the presence of multi-nucleated, osteoclast-like giant cells (2). The 32 
neoplastic stromal cells express high concentrations of receptor activator of nuclear factor 33 
kappa-B ligand (RANKL) which activates its receptor RANK on giant cells and their 34 
precursors (2). Denosumab is a human monoclonal antibody that neutralizes the activity of 35 
RANKL and therefore suppresses osteolytic bone destruction in GCTB (3). Greater than 90% 36 
elimination of giant cells after 25 week treatment with high-dose denosumab (120 mg 37 
subcutaneously on day 1, 8, 15, 28 and then every 4 weeks thereafter) has been reported 38 
(n=20) (4). Denosumab is approved by Food and Drug Administration  and European 39 
Medicines Agency for the treatment of GCTB, in adults and skeletally mature adolescents, 40 
when the tumour is deemed unresectable, requires morbid surgery, or in metastatic disease. 41 
However, uncertainties regarding treatment duration remain (5).   42 
The main safety concern of antiresorptive therapy relates to the oversuppression of bone 43 
remodelling. In adults, bisphosphonates have been implicated in the development of 44 
osteonecrosis of the jaw (ONJ) (6) and atypical femoral fractures (7) which has led to 45 
restrictions in treatment duration. High-dose denosumab therapy also causes ONJ and 46 
atypical femoral fractures in 6% and 4%, respectively of adults treated for GCTB (5). Due to 47 
the potent and rapid on-off effects on osteoclastic bone resorption, rebound hypercalcaemia 48 
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following treatment discontinuation has emerged as a relatively new adverse event specific to 49 
denosumab (8).   50 
In children and adolescents with osteogenesis imperfecta and osteoporosis,  prolonged or 51 
high dose bisphosphonate therapy has been associated with iatrogenic osteopetrosis (9) and 52 
suspected atypical femoral fractures (10,11), but never with ONJ (12) or rebound 53 
hypercalcaemia. To date, safety data for denosumab in adolescents are sparse since only 3.5% 54 
(n=10 of 282) of patients in the GCTB safety trial were adolescents (aged 13-17 years) (3). 55 
Low-dose denosumab therapy (1 mg/kg 12 weekly over 48 weeks) was found to be safe in a 56 
small number (n=10) of paediatric patients with osteogenesis imperfecta (13). However, four 57 
cases of rebound hypercalcaemia following cessation of denosumab (doses ranging from 0.5 58 
mg/kg to 120 mg in GCTB) have been reported in children (aged 8-10 years), and attributed 59 
to their physiologically higher bone turnover (14-17). The safety of prolonged use of 60 
denosumab in adolescents remains unknown due to a dearth of long term follow up studies.  61 
Here we report rebound hypercalcaemia with acute kidney injury following denosumab 62 
cessation in three young people with GCTB. Denosumab therapy had been stopped in two of 63 
them because of the development of ONJ in the adolescent and bilateral femoral cortical 64 
stress reactions in the young adult. 65 
Case Descriptions 66 
Individuals described here had a confirmed histological diagnosis of GCTB and received  67 
denosumab, 120mg subcutaneously on day 1, 8, 15, 28 and then every 4 weeks as part of a 68 
phase three clinical trial (ClinicalTrials.gov Identifier: NCT00680992) (18). All patients 69 
received fixed doses irrespective of age or weight as per the protocol but for different 70 
durations. Patient demographics, disease specifications, treatment indications, dose and 71 
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duration and reason for treatment cessation are detailed in Table 1. Table 2 details the 72 
biochemical picture at presentation of rebound hypercalcaemia and its management.  73 
Patient 1 74 
Diagnosis and initial management:  75 
A 15-year old male with biopsy-proven GCTB of the sacrum received denosumab for 76 
unresectable, recurring tumour despite previous embolisation and curettage. ‘Skeletal 77 
maturity’ was confirmed as per trial protocol (defined as radiographic evidence of at least one 78 
mature long bone [with closed epiphyseal growth plate] in ≥ 12 year old adolescents). 79 
Ongoing clinical and radiological response was seen from 3 months. 80 
Osteonecrosis of the jaw (ONJ):  81 
In the fourth year of denosumab treatment (after 44 doses), the patient (then aged 19 years) 82 
underwent dental extraction for a chipped tooth sustained whilst playing football. The risk of 83 
developing ONJ was discussed and the patient advised on dental hygiene and smoking 84 
cessation. Weighing up the risks of developing ONJ against recurrence of GCTB, denosumab 85 
was continued after ensuring complete healing of mucosa in the extraction socket with no 86 
exposed bone. Two months later he presented with acute pain at the dental extraction site. 87 
ONJ stage two was diagnosed (Figure 1A) as per the classification adopted by American 88 
Association of Oral & Maxillofacial Surgeons (6). Denosumab was stopped after a total of 46 89 
doses (cumulative dose of 98mg/kg). Swab of the affected area showed heavy growth of 90 
streptococci milleri and a moderate growth of alpha-haemolytic streptococcus. The ONJ was 91 
initially managed conservatively (amoxicillin, metronidazole and mouthwash) with poor 92 
healing, necessitating debridement and sequestrectomy of the exposed bone. A moderate 93 
amount of necrotic bone around the extraction socket of the left mandible was debrided with 94 
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subsequent full recovery. Clear demarcation between necrotic and normal bone was noted at 95 
surgery.  96 
Rebound hypercalcaemia with acute kidney injury:  97 
Seven months after stopping denosumab the patient presented with a 3-week history of 98 
nausea, vomiting and generalised body pain. Investigations identified raised serum calcium 99 
(3.1 mmol/L) (Figure 2A) and creatinine indicating acute kidney injury. Serum phosphate 100 
and alkaline phosphatase were normal, 25-hydroxy vitamin D was low and parathyroid 101 
hormone appropriately suppressed (Table 2), with normal thyroid function. An MRI scan and 102 
bone scintigraphy demonstrated no evidence of local or metastatic disease. C-terminal 103 
telopeptide of type I collagen was elevated (3.07 microg/L [normal range 0.016-0.584]) 104 
confirming increased bone resorption and the diagnosis of rebound hypercalcaemia secondary 105 
to denosumab discontinuation was made. 106 
 107 
Management and progress:  108 
Hypercalcaemia persisted despite hyperhydration (volume expansion) and resolution of the 109 
acute kidney injury. Since bisphosphonates were considered contra-indicated due to ONJ and 110 
renal failure, calcitonin (Table 2) was administered on day 0 (D0). Normocalcaemia was 111 
only achieved following a second dose on D2 (Figure 2A).  112 
Despite compliance with high volume oral hydration at home, symptomatic hypercalcaemia 113 
recurred on D19 and D33 requiring readmission for hyperhydration and calcitonin (Figure 114 
2A). On each re-challenge with calcitonin, control of hypercalcaemia was more durable. 115 
Eighteen months after stopping denosumab, he remained normocalcaemic on a high volume 116 
oral fluid regimen, ONJ had healed and there was no tumour recurrence. 117 
Patient 2 118 
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Diagnosis and initial management:  119 
A 14-year old female with sacral GCTB received neoadjuvant treatment with denosumab due 120 
to the extent of the tumour. MRI scans showed a reduction in tumour volume after 12 doses 121 
and she underwent a partial sacrectomy; histology confirmed 50% loss of giant cells in 122 
keeping with a response to denosumab. A further 6 doses of denosumab every 4 weeks post-123 
operatively were administered, with a cumulative dose of 47 mg/kg. A full recovery was 124 
made with resolution of the lower back pain noted on presentation and return to full weight 125 
bearing activities.  126 
 127 
Rebound hypercalcaemia with acute kidney injury:  128 
Six months after the last dose of denosumab, the patient (aged 15.9 years) experienced 129 
increasing back pain, paraesthesia of her legs and nausea. An MRI scan showed no evidence 130 
of recurrence or metastases. Investigations revealed marked hypercalcaemia (serum calcium 131 
3.4 mmol/L) (Figure 2B) with acute kidney injury. Denosumab-induced rebound 132 
hypercalcaemia was diagnosed following exclusion of other causes, i.e hyperparathyroidism 133 
and thyrotoxicosis (Table 2). 25 hydroxy vitamin D levels were very low.  134 
Management and progress:  135 
Hyperhydration (150% maintenance) was commenced and single dose of frusemide (1 136 
mg/kg) was administered on D0 to induce calciuresis. Since continued hyperhydration over 5 137 
days was unsuccessful in resolving hypercalcaemia, low dose pamidronate (Table 2) was 138 
administered on D5 and D6 (Figure 2B). Calcium normalised on D7 and previously 139 
suppressed parathyroid hormone improved to 29 ng/L. A single dose of cholecalciferol 140 
(150,000 IU) followed by daily vitamin D (400 IU) and calcium supplements (1.2 g three 141 
times a day) were commenced. Symptomatic hypocalcaemia nevertheless occurred, requiring 142 
one bolus dose of IV calcium, followed by oral calcium supplementation which was weaned 143 
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over 4 weeks. Severe bone pain, initially managed with ibuprofen and morphine, responded 144 
very well to pamidronate. Serum calcium remains stable one year after pamidronate with no 145 
further episodes of rebound hypercalcaemia. GCTB remains under remission.  146 
 147 
Patient 3 148 
Diagnosis and initial management: 149 
A 40-year old male, with very large and vascular GCTB of the scapula opted for denosumab 150 
treatment. Clinical and radiologic response to treatment was achieved and denosumab 151 
continued to avoid morbid surgical resection of the whole scapula. After 51 doses of 152 
denosumab therapy (cumulative dose of 51 mg/kg) the patient presented with bilateral thigh 153 
pain. Plain radiographs did not reveal any identifiable lesions; therefore a single photon 154 
emission computed tomography scan was undertaken which revealed increased tracer uptake 155 
on the medial  cortex  of  both  proximal  femora, the area of clinical concern (Figure 1B). 156 
Since such femoral cortical stress reactions are association with antiresorptive agents (7), 157 
denosumab therapy was stopped.  Thigh pain settled with denosumab cessation and did not 158 
necessitate any treatment.  159 
 160 
Rebound hypercalcaemia and acute kidney injury: 161 
The patient presented to the emergency department 5.5 months after denosumab cessation 162 
with drowsiness, polyuria, polydipsia and vomiting. On presentation, hypercalcaemia (serum 163 
calcium 4.27 mmol/L) and acute kidney injury (Table 2) was diagnosed, which was managed 164 
with hyperhydration and ibandronate (Figure 2C). Parathyroid hormone was appropriately 165 
suppressed. The patient presented again on D33 with a further episode of hypercalcaemia, 166 
which was managed with hyperhydration alone.  At restaging, 7.5 months from stopping 167 
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denosumab, a relatively small focal recurrence was identified relative to the overall 168 
dimensions of the initial tumour on MRI and was confirmed on biopsy. This has been 169 
managed by subtotal scapulectomy.    170 
 171 
Discussion  172 
Prolonged, potent antiresorptive therapy (including bisphosphonates and denosumab) in 173 
adults is associated with ONJ and atypical femoral fractures. To date, these serious adverse 174 
effects have not been reported in children and adolescents. Here we report the first case of 175 
ONJ in an adolescent (P1) and femoral cortical stress reactions in a young adult (P3) 176 
receiving treatment with fixed high-dose denosumab for GCTB. The fact that these two 177 
patients and another adolescent also developed rebound hypercalcaemia and acute kidney 178 
injury following treatment cessation raises serious safety questions. All patients were naïve to 179 
chemotherapy, radiotherapy, bisphosphonates and had no evidence of metastatic disease, 180 
confirming the causative role of denosumab in these complications.  181 
Antiresorptive therapy in children is generally considered safe. However, the case of a child 182 
who developed iatrogenic osteopetrosis with tube-like, dense metaphyses during prolonged, 183 
high-dose bisphosphonate therapy has raised safety concerns amongst paediatric bone 184 
specialists (9). Side-effects of standard-dose bisphosphonate therapy include typical 185 
metaphyseal sclerotic bands which are also seen in denosumab treatment (19). 186 
Bisphosphonates have also been associated with suspected atypical femoral fractures in 187 
children (10,11) although not confirmed in larger series (20,21). Several studies have 188 
assessed the risk of developing ONJ in bisphosphonate-treated children following dental 189 
treatment (22, 23), however no cases have been reported so far.  190 
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Medication  or antiresorptive agent-related ONJ (6) has been associated with risk factors such 191 
as smoking, old age, poor oral hygiene, invasive dental procedures, serious comorbidities and 192 
concomitant treatments (18). ONJ has been reported in nearly six per cent of GCTB treated 193 
patients (5). Patient 1 developed ONJ following a dental extraction, a known major risk factor 194 
reported by 52-61% of adult ONJ patients, with greatest risk in those on intravenous 195 
bisphosphonates (6). He was also a smoker and had poor dental hygiene, hence had several 196 
risk factors for developing ONJ.  197 
The risk of ONJ in adults on antiresorptive treatment is dose and duration dependent (5). The 198 
fixed denosumab dose of 120mg 4 weekly is based on 90% suppression of urinary N-199 
telopeptide normalised to urinary creatinine (uNTx/Cr) in adults (n=373) with bone 200 
metastases from solid tumours (24). Whilst to date no study has determined appropriate 201 
paediatric doses, these high doses were anticipated to be safe in adolescents weighing over 202 
45kg with closed growth plates, extrapolated from data in adults with GCTB weighing as low 203 
as 38kg (18). However, bone metabolism in young people differs from adults, and includes 204 
bone modelling and elongation, with bone accrual into their late twenties, long after closure 205 
of growth plates (25). The teenage GCTB patients reported here, and those in other reports 206 
(14,15), indicate an urgent need to consider weight-based dosing and systematic safety 207 
studies. Although the rate and extent of uNTx/Cr suppression are reported to remain constant 208 
at denosumab doses above 0.3 mg/kg, the duration of maximum suppression increases with 209 
increasing doses (26,27). Moreover, denosumab displays a dose-proportional increase in 210 
exposure at doses higher than 60mg. Of note, the incidence of denosumab related ONJ in 211 
prostate cancer patients is reportedly higher in clinical practice (28) when compared to trials 212 
(29) (11·4% vs 2·3% respectively). Hence, the clinical implications and safety of cumulative 213 
doses over a prolonged period of time require further studies (30). 214 
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Patient 3 developed femoral cortical stress reactions in the proximal femur bilaterally. 215 
Atypical femoral fractures have been linked to denosumab (5). The incidence of femoral 216 
cortical stress reactions in metastatic bone disease patients receiving denosumab is reported 217 
to be around 4·5% (31). Femoral cortical stress reaction is recognised as a prodrome of 218 
atypical femoral fracture (31-34). Unlike previous reports P3 did not have osteoporosis, 219 
metastatic disease and was not exposed to bisphosphonates or corticosteroids indicating the 220 
independent role of denosumab in the causation of femoral cortical stress reactions.   221 
Hypocalcaemia during denosumab treatment is well recognised as a sign of rapid suppression 222 
of bone remodelling (3), however rebound hypercalcaemia due to rapid release of previously 223 
suppressed remodelling is less known, hence unmonitored. There are four reported cases of 224 
rebound hypercalcaemia following denosumab cessation in children, occurring between 7 225 
weeks - 5 months after treatment cessation. Two juvenile patients with GCTB received high 226 
dose denosumab (14,15), the third, a 9 year old boy with fibrous dysplasia, received a starting 227 
denosumab dose of 1 mg/kg increasing up to 1.75 mg/kg with 0.25 mg/kg dose increments 3 228 
monthly (16) and the fourth, an 8 year old girl with Paget’s disease received 0.5 mg/kg (17).   229 
Rebound hypercalcaemia is due to osteoclast overactivity after denosumab cessation and is 230 
thought to be a feature of skeletally immature children due to high bone turnover. Quite in 231 
contrast, P3, aged 40, and another reported adult, aged 60, also experienced rebound 232 
hypercalcaemia (8), indicating that this side effect is not restricted to young patients. Whilst 233 
hypercalcaemia can be a sign of tumour reactivation, there was no such evidence in our 234 
patients. Similar to previous reports (14,15) all our patients had parathyroid hormone-235 
independent hypercalcaemia. Suppressed parathyroid hormone noted at presentation 236 
improved following treatment of hypercalcaemia (P2). 237 
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Currently, there are no data on the incidence of rebound hypercalcaemia, and no monitoring 238 
or management guidelines. The mean half-life of denosumab after cessation is reported to be 239 
29 days (range 25-35 days) (27). However, the clearance is likely to be longer in individuals 240 
with accumulated doses, hence the occurrence of rebound hypercalcaemia as late as 7 months 241 
from treatment cessation. Possibly, the presence of vitamin D deficiency in P1 and P2 242 
delayed their presentation. Hypercalcaemia responded poorly to hydration alone, so P1 was 243 
managed with calcitonin in the setting of ONJ and renal failure, and P2 and P3 with low dose 244 
pamidronate and ibandronate. A previous report described resistance to a combined use of 245 
calcitonin, pamidronate and corticosteroids, necessitating the use of low dose denosumab 246 
(15). Whilst the prolonged antiresorptive action of bisphosphonates is an effective treatment 247 
for hypercalcaemia in this setting, the presence of acute kidney injury increases the risk of 248 
bisphosphonate-induced renal failure. None of the patients reported here were monitored for 249 
rebound hypercalcaemia and presented unwell and in pain, requiring extensive investigations 250 
to rule out other causes of hypercalcaemia. The increasing use of denosumab necessitates 251 
monitoring and increased awareness amongst clinicians and patients.  252 
Conclusions: 253 
The effect that denosumab has on GCTB size reduction is remarkable, but the necessity for 254 
high-dose long-term antiresorptive therapy comes at the price of suppression of bone 255 
remodelling which in adults includes the risk of osteonecrosis of the jaw and atypical femoral 256 
fractures. Denosumab, with its potent suppression-release effects has introduced the 257 
additional complications of hypocalcaemia at drug commencement and rebound 258 
hypercalcemia after discontinuation. This first case of ONJ in an adolescent and the 259 
substantial morbidity from rebound hypercalcaemia after treatment discontinuation in our 260 
young patients stresses the need to consider weight-adjusted dosing, frequency and duration 261 
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of treatment, and develop tools to monitor treatment. A systematic monitoring of serum 262 
calcium and pain for a minimum of 7 months after treatment cessation should be adopted.  263 
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Figure 1: Side effects during denosumab therapy:  
Fig 1A: Osteonecrosis of the jaw (circled) in patient 1, demonstrating an area of non- healing, 
exposed bone in the mandible following the removal of a permanent lower left first molar 
tooth. 
Fig 1B: Single photon emission computed tomography scan on patient 3 demonstrating 
increased tracer uptake representing bilateral femoral cortical stress reactions (arrows), and 
the giant cell tumour of the right scapula. 
 
Figure 2: Rebound hypercalcaemia following denosumab discontinuation: Serum calcium 
levels (corrected for albumin, cCa
2+
) at presentation and response to treatment in patient 1 
(A), patient 2 (B) and patient 3 (C). Interventions are indicated with arrows and lower (LL) 
and upper (UL) normal ranges for serum calcium are indicated by horizontal lines.  
 
 
 
 
 
